Pembrolizumab is a type of medication known as an immunotherapy. It works by helping your immune system fight cancer. Pembrolizumab targets a specific protein on the surface of certain immune cells, which can help your body recognize and attack cancer cells more effectively. In this clinical trial, pembrolizumab is being tested to see how safe it is for children with advanced melanoma or other types of tumors that have come back or are difficult to treat. The study aims to find out how well pembrolizumab works in shrinking these tumors and what side effects it might cause.

Advanced Melanoma – Advanced melanoma is a type of skin cancer that has spread beyond the original site to other parts of the body. It begins in the melanocytes, which are the cells responsible for producing melanin, the pigment that gives skin its color. As the disease progresses, it can invade nearby tissues and organs, making it more challenging to manage. The spread of melanoma to distant organs is known as metastasis, which can affect the lungs, liver, brain, and bones. The progression of advanced melanoma can vary, with some cases spreading rapidly while others may progress more slowly.

PD-L1 Positive Malignant Solid Tumor – PD-L1 positive malignant solid tumors are characterized by the expression of the PD-L1 protein on the surface of cancer cells. This protein can help tumors evade the immune system by inhibiting the activity of immune cells. These tumors can occur in various organs and tissues, leading to a range of symptoms depending on their location. As the disease progresses, the tumor may grow and spread to other parts of the body, a process known as metastasis. The presence of PD-L1 can influence the tumor’s behavior and its interaction with the immune system.

Relapsed or Refractory Classical Hodgkin Lymphoma (rrcHL) – Classical Hodgkin lymphoma is a type of cancer that originates in the lymphatic system, specifically affecting a type of white blood cell called lymphocytes. In relapsed or refractory cases, the disease returns after treatment or does not respond to standard therapies. The progression involves the growth of abnormal lymphocytes, which can form tumors in lymph nodes and other parts of the body. As the disease advances, it can impair the immune system’s ability to function properly. The spread of lymphoma can lead to symptoms such as swollen lymph nodes, fever, and weight loss.

Microsatellite Instability-High (MSI-H) Solid Tumors – MSI-H solid tumors are characterized by a high level of genetic mutations due to defects in the DNA mismatch repair system. These tumors can occur in various organs, including the colon, stomach, and endometrium. The progression of MSI-H tumors involves the accumulation of genetic errors, which can lead to uncontrolled cell growth and tumor development. As the disease advances, these tumors may invade surrounding tissues and metastasize to distant sites. The high mutation rate in MSI-H tumors can influence their behavior and response to the immune system.

Tumor Mutational Burden-High (TMB-H) Solid Tumors – TMB-H solid tumors are defined by a high number of mutations within the tumor’s DNA. These mutations can lead to the production of abnormal proteins that may be recognized by the immune system. TMB-H tumors can develop in various tissues and organs, leading to diverse clinical presentations. As the disease progresses, the tumor may grow and spread to other parts of the body, a process known as metastasis. The high mutational burden can affect the tumor’s characteristics and its interaction with the immune system.